The effects of levonantradol hydrochloride on tumor growth and therapy.
The effects of levonantradol on tumor growth, both directly and in combination with the cytotoxic agent cyclophosphamide, were determined. Levonantradol hydrochloride administered alone had no effect on the progression of either murine sarcoma 180J or leukemia L-1210. Likewise, the increased survival obtained in both tumor systems with cyclophosphamide was not altered by concurrent administration of levonantradol hydrochloride. Levonantradol did not affect the incidence or extent of artificial melanotic lung metastases, nor did it modify lymphoreticular cell stimulation. These data support the use of levonantradol in conjunction with chemotherapy in cancer patients.
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D002478:Cells, Cultured; D004347:Drug Interactions; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy / Q000473:pathology; D008264:Macrophages / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology*; D010617:Phenanthridines / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology; D013237:Stereoisomerism
D000932:Antiemetics; D010617:Phenanthridines; C025490:nantradol